Results of two Phase 1, Randomized, Double-blind, Placebo-controlled, Studies (Ascending Single-dose and Multiple-dose Studies) to Determine the Safety, Tolerability, and Pharmacokinetics of Orally Administered LX9211 in Healthy Participants-Reference-Cited by-同舟云学术

Results of two Phase 1, Randomized, Double-blind, Placebo-controlled, Studies (Ascending Single-dose and Multiple-dose Studies) to Determine the Safety, Tolerability, and Pharmacokinetics of Orally Administered LX9211 in Healthy Participants

Published:2021-06 Issue:6 Volume:43 Page:1029-1050
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Bundrant LuAnn,Hunt Thomas L.,Banks Phil,Gopinathan Suma,Boehm Kristi A.,Kassler-Taub Kenneth,Tyle Praveen,Wilson Alan,Warner Chris,Wason Suman

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference7 articles.

1. Neuropathic pain: a maladaptive response of the nervous system to damage;Costigan;Annu Rev Neurosci,2009

2. The evidence for pharmacological treatment of neuropathic pain;Finnerup;Pain,2010

3. Systemic review and meta-analysis of pharmacological therapies for pain associated with postherpetic neuralgia and less common neuropathic conditions;Snedecor;Int J Clin Pract,2014

4. Inhibition of AAK1 kinase as a novel therapeutic approach to treat neuropathic pain;Kostich;J Pharmacol Exp Ther,2016

5. LX9211 A Selective Inhibitor of AAK1 (Adapter-Associated Kinase) for Neuropathic Pain? Some Thoughts on Selectivity and Specificity;Hesselink;Austin Neurol,2018

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An overview of the safety and efficacy of LX-9211 in treating neuropathic pain conditions;Expert Opinion on Investigational Drugs;2024-07-08

2. Efficacy and Safety of LX9211 for Relief of Diabetic Peripheral Neuropathic Pain (RELIEF-DPN 1): Results of a Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study;Diabetes Care;2024-06-19

3. Neuropathic pain: Evidence based recommendations;La Presse Médicale;2024-06

4. An extract of phase II and III trials on recent developments in managing neuropathic pain syndromes: diabetic peripheral neuropathy, trigeminal neuralgia, and postherpetic neuralgia;Expert Opinion on Emerging Drugs;2024-02-29

5. Investigational Drugs for the Treatment of Postherpetic Neuralgia: Systematic Review of Randomized Controlled Trials;International Journal of Molecular Sciences;2023-08-20